CVE:DMA

DiaMedica Therapeutics (DMA) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free DMA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 27,250 shs
Average Volume: 6,619 shs
Market Capitalization: C$36.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get DiaMedica Therapeutics alerts:

Ad Priority Gold

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Ad Priority Gold

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

DMA Stock News Headlines

February 16, 2024 | morningstar.com

DiaMedica Therapeutics Inc DMAC

March 31, 2023 | seekingalpha.com

DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript

April 18, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

February 24, 2023 | nasdaq.com

Cerevel Therapeutics Holdings (CERE) Shares Cross Below 200 DMA

October 26, 2022 | seekingalpha.com

DiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trial

August 12, 2022 | finance.yahoo.com

MEXC Activated the "Investor Protection Fund" in Response to the Dragoma (DMA) Incident, and Launched the "Potion" Airdrop Compensation Benefits

July 8, 2022 | marketwatch.com

DiaMedica Therapeutics Announces Clinical Hold of DM199 Trial, Shares Fall 31%

May 7, 2022 | seekingalpha.com

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call Transcript

See More Headlines

Receive DMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: CVE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: CVE:DMA
CUSIP: N/A
CIK: N/A
Web: www.diamedica.com
Phone: +1-763-4965454
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.48
Quick Ratio: 3.37

Sales & Book Value

Annual Sales: C$503,657.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 9.33
Book Value: C$0.17 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 7,856,880
Free Float: N/A
Market Cap: C$36.38 million
Optionable: Not Optionable
Beta: N/A

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Rick Pauls M.B.A. (Age 48)
MBA, Pres, CEO & Director
Dr. Todd A. Verdoorn (Age 58)
Chief Scientific Officer
Mr. Scott B. Kellen C.A. (Age 54)
CFO & Company Sec.
Mr. Edward B. Rady (Age 70)
Chief Commercial Advisor
Dr. Dennis D. Kim M.D. (Age 49)
MBA, Consulting Chief Medical Officer

Key Competitors

View All Competitors

This page (CVE:DMA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

DiaMedica Therapeutics (DMA) Stock Price, News & Analysis

About DiaMedica Therapeutics

DMA Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info